SUS

The Designer Behind Lark Office Suite by Bytedance

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- ArtsBerry invited the Senior Designer behind Lark Suite to share her creative design ideas and process of the suite of office collaboration tools focusing on cloud-based file management and document and spreadsheet editing.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- ArtsBerry invited the Senior Designer behind Lark Suite to share her creative design ideas and process of the suite of office collaboration tools focusing on cloud-based file management and document and spreadsheet editing.
  • Lark is an enterprise collaboration platform developed by ByteDance (Parent Company of TikTok) and first released to the public in 2019.
  • Lark Office Suite is called Chinese version of "Slack" and "Microsoft Teams."
  • He led to release, Lark became No.3 in the Chinese office platform with 4.6 million monthly active users in 2021.

Wellsheet Recognized as a Sample Vendor in Smart EHR UI in a Gartner Report

Retrieved on: 
Wednesday, July 20, 2022

Wellsheet Inc. , the leading Smart EHR UI provider reducing clinician burnout and increasing EHR efficiency and usability, announced today that Gartner has named Wellsheet as a Sample Vendor in the Smart EHR UI category in the Gartner Hype Cycle for Digital Care Delivery Including Virtual Care, 2022.

Key Points: 
  • Wellsheet Inc. , the leading Smart EHR UI provider reducing clinician burnout and increasing EHR efficiency and usability, announced today that Gartner has named Wellsheet as a Sample Vendor in the Smart EHR UI category in the Gartner Hype Cycle for Digital Care Delivery Including Virtual Care, 2022.
  • Wellsheets Smart EHR UI reduces the time and effort to find, access and share relevant clinical information in real-time - no other Smart EHR UI, voice AI, or cloud provider is proven to do this today, said Craig Limoli, CEO and founder of Wellsheet.
  • Smart EHR UI solutions can improve usability and mitigate clinician burnout by reducing the time and effort to find relevant clinical information within the EHR.
  • To learn more about how you can deploy Wellsheets Smart EHR UI to reduce clinician burnout and improve your bottom line:

Global Single-use Bioprocessing Market to 2028 - Opportunity and Demand Analysis

Retrieved on: 
Monday, February 21, 2022

According to this report the global single-use bioprocessing market is anticipated to grow at a CAGR of 12.6% during the forecast period.

Key Points: 
  • According to this report the global single-use bioprocessing market is anticipated to grow at a CAGR of 12.6% during the forecast period.
  • Single-use systems (SUS) refer to biopharmaceutical manufacturing (bioprocessing) equipment that is designed for single-use and then discarded.
  • Single-use facilities are anticipated to dominate bioprocessing in terms of the number of facilities, bioprocessing professionals' work, and the number of products manufactured, especially at clinical scales.
  • North America is anticipated to witness healthy growth in the single-use bioprocessing market during the forecast period.

Worldwide Single-use Bioprocessing Industry to 2028 - Featuring Sartorius, Eppendorf and General Electric Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022

SUS is widely used in preclinical, clinical, biopharmaceutical manufacturing and is rapidly adopted in the manufacturing of commercial products.

Key Points: 
  • SUS is widely used in preclinical, clinical, biopharmaceutical manufacturing and is rapidly adopted in the manufacturing of commercial products.
  • Single-use facilities are anticipated to dominate bioprocessing in terms of the number of facilities, bioprocessing professionals' work, and the number of products manufactured, especially at clinical scales.
  • Based on the end-users, the single-use biopharmaceutical market has been segmented into biopharmaceutical manufacturers, academic & clinical research institutes, and others.
  • North America is anticipated to witness healthy growth in the single-use bioprocessing market during the forecast period.

Ultragenyx Announces Approval of DojolviĀ® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Retrieved on: 
Monday, August 23, 2021

We are grateful to the community of patients, caregivers and physicians whose efforts have contributed to this important approval.

Key Points: 
  • We are grateful to the community of patients, caregivers and physicians whose efforts have contributed to this important approval.
  • Outside of the U.S., patients have had access to Dojolvi through named patient and early access programs.
  • LC-FAOD are a group of autosomal recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to convert long-chain fatty acids into energy.
  • Other current treatment options for LC-FAOD include avoidance of fasting, low-fat/high-carbohydrate diets, carnitine and even-carbon medium-chain triglyceride (MCT) oil, a medical food product.